rosolutamide
AssetAlso ASC-JM-17, AJ201
Degrades mutant androgen receptor and induces Nrf2 and heat shock proteins
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Spinal and bulbar muscular atrophy
Phase 3, prnewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains5
- Owner and partners1
- Evidence for its targets5
- Competitors7
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.